EDUARDO FERREIRA BORBA NETO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
31 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 31
conferenceObject BASELINE CHARACTERISTICS OFA LONGITUDINAL, MULTINATIONAL, MULTIETHNIC STUDYOF LUPUS PATIENTS, WITH ORWITHOUT LUPUS NEPHRITIS(2023) NIETO, Romina; QUINTANA, Rosana; BORBA, Eduardo; HERNANDEZ, Lucia; FERNANDEZ, Diana; MAURELLI, Laura; ALBA, Paula; BORDON, Florencia; ARIZPE, Fernando; BERBOTTO, Guillermo; SERRANO, Rosa; BERTOLACCINI, Maria; KERSBERG, Eduardo; GARGIULO, Maria; RODRIGUEZ, Anabella; BARBOSA, Vitalina; GASPARIN, Andrese; CAVALCANTI, Fernando; ALVES, Laissa; PARENTE, Luciana; OLIVEIRA, Lucas de; NEIRA, Oscar; MASSARDO, Loreto; AROCA, Gustavo; NIETO, Ivana; MENDEZ, Paul; IGLESIAS, Antonio; ZUNIGA, Andres; VERA, Olga; PEREZ, Mario; NARES, Eduardo; AMEZCUA, Luis; GONZALEZ, Yelitza; GONZALEZ, Octavio; GALARZA, Dionicio; VAZQUEZ, Carolina; BARRIOS, Marcelo; LINARES, Magaly; REATEGUI, Cristina; QUIROS, Ana; POLANCO, Teresandris; PIZZAROSSA, Carina; REBELLA, Martin; CRESPO, Maria; DANZA, Alvaro; BONFA, Eloisa; ALARCON, Graciela; ZAZZETTI, Federico; ORILLION, Ashley; SBARIGIA, Urbano; ESTEL, Guillermo Pons- Pleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL)(2017) SALINAS, M. J. Haye; CAEIRO, F.; SAURIT, V.; ALVARELLOS, A.; WOJDYLA, D.; SCHERBARTH, H. R.; SILVA, A. C. de O. e; BRENOL, J. C. Tavares; COSTALLAT, L. T. Lavras; NEIRA, O. J.; GAMARRA, A. Iglesias; VASQUEZ, G.; LLERENA, G. A. Reyes; BARILE-FABRIS, L. A.; SILVEIRA, L. H.; POZO, M. J. Sauza del; VASQUEZ, E. M. Acevedo; LOZANO, J. L. Alfaro; SPINETTI, M. H. Esteva; ALARCON, G. S.; PONS-ESTEL, B. A.; BONFA, Eloisa; BORBA, Eduardo FerreiraObjectives The objectives of this study were to examine the demographic and clinical features associated with the occurrence of pleuropulmonary manifestations, the predictive factors of their occurrence and their impact on mortality in systemic lupus erythematosus (SLE) patients. Materials and methods The association of pleuropulmonary manifestations with demographic and clinical features, the predictive factors of their occurrence and their impact on mortality were examined in GLADEL patients by appropriate univariable and multivariable analyses. Results At least one pleuropulmonary manifestation occurred in 421 of the 1480 SLE patients (28.4%), pleurisy being the most frequent (24.0%). Age at SLE onset 30 years (OR 1.42; 95% CI 1.10-1.83), the presence of lower respiratory tract infection (OR 3.19; 95% CI 2.05-4.96), non-ischemic heart disease (OR 3.17; 95% CI 2.41-4.18), ischemic heart disease (OR 3.39; 95% CI 2.08-5.54), systemic (OR 2.00; 95% CI 1.37-2.91), ocular (OR 1.58; 95% CI 1.16-2.14) and renal manifestations (OR 1.44; 95% CI 1.09-1.83) were associated with pleuropulmonary manifestations, whereas cutaneous manifestations were negatively associated (OR 0.47; 95% CI 0.29-0.76). Non-ischemic heart disease (HR 2.24; 95% CI 1.63-3.09), SDI scores 1 (OR 1.54; 95% CI 1.10-2.17) and anti-La antibody positivity (OR 2.51; 95% CI 1.39-4.57) independently predicted their subsequent occurrence. Cutaneous manifestations were protective of the subsequent occurrence of pleuropulmonary manifestations (HR 0.62; 95% CI 0.43-0.90). Pleuropulmonary manifestations independently contributed a decreased survival (HR: 2.79 95% CI 1.80-4.31). Conclusion Pleuropulmonary manifestations are frequent in SLE, particularly pleuritis. Older age, respiratory tract infection, cardiac, systemic and renal involvement were associated with them, whereas cutaneous manifestations were negatively associated. Cardiac compromise, SDI scores 1 and anti-La positivity at disease onset were predictive of their subsequent occurrence, whereas cutaneous manifestations were protective. They independently contributed to a decreased survival in these patients.
conferenceObject Predictive Factors According to Type of Infection in Systemic Lupus Erythematosus Patients: Data from a Multi-Ethnic, Multi-National, Latin-American Cohort(2017) PIMENTEL-QUIROZ, Victor R.; UGARTE-GIL, Manuel; PONS-ESTEL, Guillermo J.; WOJDYLA, Daniel; CARDIEL, Mario; PASCUAL-RAMOS, Virginia; TORRE, Ignacio Garcia-De la; BARILE, Leonor; AMIGO, Mary Carmen; SILVEIRA, Luis H.; POZO, Maria Josefina Sauza del; GUIBERT-TOLEDANO, Marlene; REYES, Gil A.; IGLESIAS-GAMARRA, Antonio; VASQUEZ, Gloria; MOLINA, Jose Fernando; GOMEZ-PUERTA, Jose A.; GONZALEZ, Luis Alonso; CHACON-DIAZ, Rosa; SPINETTI, Maria H. Esteva; ABADI, Isaac; ACEVEDO-VASQUEZ, Eduardo M.; ALFARO-LOZANO, Jose; SEGAMI, Ines; MASSARDO, Loreto; NEIRA, Oscar; SATO, Emilia; BONFA, Eloisa; BORBA, Eduardo; ALARCON, Graciela S.; PONS-ESTEL, BernardoconferenceObject Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort(2019) MIMICA, Milena; PADILLA, Oslando; AGUILERA, Felipe; CAVALCANTI, Fernando; BORBA, Eduardo; GUIBERT-TOLEDANO, Marlene; CHACON-DIAZ, Rosa; VASQUEZ, Gloria; PONS-ESTEL, Guillermo; CARDIEL, Mario; NEIRA, Oscar; AMIGO, Mary-Carmen; BONFA, Eloisa; ALARCON, Graciela; PONS-ESTEL, Bernardo A.; MASSARDO, Loreto- Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)(2017) UGARTE-GIL, Manuel Francisco; WOJDYLA, Daniel; PONS-ESTEL, Guillermo J.; CATOGGIO, Luis J.; DRENKARD, Cristina; SARANO, Judith; BERBOTTO, Guillermo A.; BORBA, Eduardo F.; SATO, Emilia Inoue; BRENOL, Joao C. Tavares; URIBE, Oscar; GOMEZ, Luis A. Ramirez; GUIBERT-TOLEDANO, Marlene; MASSARDO, Loreto; CARDIEL, Mario H.; SILVEIRA, Luis H.; CHACON-DIAZ, Rosa; ALARCON, Graciela S.; PONS-ESTEL, Bernardo A.Objective To evaluate disease activity statuses' (DAS') impact on systemic lupus erythematosus (SLE) outcomes. Materials and methods Four DAS were defined: remission off-therapy: SLE Disease Activity Index (SLEDAI)=0, no prednisone or immunosuppressive drugs (IS); remission on-therapy: SLEDAI=0, prednisone <= 5 mg/day and/or IS (maintenance); low (L) DAS: SLEDAI <= 4, prednisone <= 7.5 mg/day and/or IS (maintenance); non-optimally controlled: SLEDAI >4 and/or prednisone >7.5 mg/day and/or IS (induction). Antimalarials were allowed in all. Predefined outcomes were mortality, new damage (increase of at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) point) and severe new damage (increase of at least 3 SDI points). Univariable and multivariable Cox regression models were performed to define the impact of DAS, as time-dependent variable, on these outcomes. Results 1350 patients were included, 79 died during follow-up, 606 presented new and 177 severe new damage. In multivariable analyses, remission (on/off-therapy) was associated with a lower risk of new (HR 0.60; 95% CI 0.43 to 0.85), and of severe new damage (HR 0.32; 95% CI 0.15 to 0.68); low disease activity status (LDAS) was associated with a lower risk of new damage (HR 0.66; 95% CI 0.48 to 0.93) compared with non-optimally controlled. No significant effect on mortality was observed. Conclusions Remission was associated with a lower risk of new and severe new damage; LDAS with a lower risk of new damage after adjusting for other damage confounders.
conferenceObject PREGNANCYOUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM A MULTIETHNIC, MULTINATIONAL LATIN AMERICAN COHORT(2023) MORALES, Rosa M. Serrano; NIETO, Romina; QUINTANA, Rosana; ALBA, Paula; PORTA, Sabrina; HERNANDEZ, Lucia; BERBOTTO, Guillermo A.; BELLOMIO, Veronica; SILVA, Nilzio A. da; MONTICIELO, Odirlei Andre; CAVALCANTI, Fernando S.; RIBEIRO, Francinne Machado; BORBA, Eduardo F.; BONFA, Eloisa; MASSARDO, Loreto; MARTINEZ, Gustavo Aroca; BONFANTI, Andres Cadena; LOPEZ, Gerardo Quintana; MORENO, Mario; VALERIO, Jorge A. Esquivel; COLMAN, Maria I. Acosta; NICORA, Astrid Paats; TRUJILLO, Claudia S. Mora; SCOLNIK, Marina; FERNANDEZ, Diana; SOAJE, Carmen Funes; SAURIT, Veronica; GARCIA, Mercedes; KERZBERG, Eduardo; GOMEZ, Graciela; PISONI, Cecilia; REIS NETO, Edgard Torres dos; HERRERA, Iris Guerra; QUIROGA, Oscar Neira; CANAS, Carlos A.; SALINAS, Miguel A. Saavedra; HERNANDEZ, Margarita Portela; LOYO, Hilda Fragoso; SILVEIRA, Luis H.; UGARTE-GIL, Manuel; QUIROZ, Armando Calvo; LOUIS, Roberto Munoz; ROBAINA, Ricardo; JUAREZ, Vicente; DANZA, Alvaro; TORO-GUTIERREZ, Carlos E.; MENDOZA, Carlos Abud; MALVAR, Ana; ALARCON, Graciela S.; ORILLION, Ashley; SBARIGIA, Urbano; ZAZZETTI, Federico; PONS-ESTEL, Guillermo J.; PONS-ESTEL, Bernardo A.- Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort(2019) PIMENTEL-QUIROZ, V. R.; UGARTE-GIL, M. F.; HARVEY, G. B.; WOJDYLA, D.; PONS-ESTEL, G. J.; QUINTANA, R.; ESPOSTO, A.; GARCIA, M. A.; CATOGGIO, L. J.; CARDIEL, M. H.; BARILE, L. A.; AMIGO, M-C; I, E. Sato; BONFA, E.; BORBA, E.; COSTALLAT, L. T. Lavras; NEIRA, O. J.; MASSARDO, L.; GUIBERT-TOLEDANO, M.; CHACON-DIAZ, R.; ALARCON, G. S.; PONS-ESTEL, B. A.; SORIANO, Enrique R.; RECALDE, Maria Flavia Ceballos; VELOZO, Edson; MANNI, Jorge A.; GRIMAUDO, Sebastian; SARANO, Judith; MALDONADO-COCCO, Jose A.; ARRIOLA, Maria S.; GOMEZ, Graciela; MARCOS, Ana Ines; MARCOS, Juan Carlos; SCHERBARTH, Hugo R.; LOPEZ, Jorge A.; MOTTA, Estela L.; DRENKARD, Cristina; GAMRON, Susana; BULIUBASICH, Sandra; ONETTI, Laura; CAEIRO, Francisco; ALVARELLOS, Alejandro; SAURIT, Veronica; GENTILETTI, Silvana; QUAGLIATTO, Norberto; GENTILETTI, Alberto A.; MACHADO, Daniel; ABDALA, Marcelo; PALATNIK, Simon; BERBOTTO, Guillermo A.; BATTAGLIOTTI, Carlos A.; SOUZA, Alexandre Wagner S.; BERTOLO, Manoel Barros; COIMBRA, Ibsen Bellini; BRENOL, Joao C. Tavares; MONTICIELO, Odirlei; XAVIER, Ricardo; CAVALCANTI, Fernando de Souza; DUARTE, Angela Luzia Branco; MARQUES, Claudia Diniz Lopes; SILVA, Nilzio Antonio da; SILVA, Ana Carolina de O e; PACHECO, Tatiana Ferracine; MOLINA-RESTREPO, Jose Fernando; MOLINA-LOPEZ, Javier; VASQUEZ, Gloria; RAMIREZ, Luis A.; URIBE, Oscar; IGLESIAS-GAMARRA, Antonio; IGLESIAS-RODRIGUEZ, Antonio; EGEA-BERMEJO, Eduardo; GUZMAN-MORENO, Renato A.; RESTREPO-SUAREZ, Jose F.; REYES-LLERENA, Gil Alberto; HERNANDEZ-MARTINEZ, Alfredo; JACOBELLI, Sergio; GUZMAN, Leonardo R.; GARCIA-KUTZBACH, Abraham; CASTELLANOS, Claudia; CAJAS, Erwin; PASCUAL-RAMOS, Virginia; SILVEIRA, Luis H.; TORRE, Ignacio Garcia De La; OROZCO-BAROCIO, Gerardo; ESTRADA-CONTRERAS, Magali L.; POZO, Maria Josefina Sauza del; BACA, Laura E. Aranda; QUEZADA, Adelfia Urenda; HUERTA-YANEZ, Guillermo F.; ACEVEDO-VAZQUEZ, Eduardo M.; ALFARO-LOZANO, Jose Luis; CUCHO-VENEGAS, Jorge M.; SEGAMI, Maria Ines; CHUNG, Cecilia P.; ALVA-LINARES, Magaly; ABADI, Isaac; RANGEL, Neriza; SNIH, Soham Al Snih Al; ESTEVA-SPINETTI, Maria H.; VIVAS, JorgeAim The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). Methods A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. Results Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20-37) years and 47.8 (17.9-68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48-0.99; p = 0.0440) was protective, while doses of prednisone >15 and <= 60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69-10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35-16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10-2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01-1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11-1.34; p < 0.0001) were predictive factors of serious infections. Conclusions Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients.
conferenceObject Clinical Features, Damage Accrual and Survival in Patients with Familial Systemic Lupus Erythematosus (SLE): Data from a Multiethnic, Multinational Latin American Lupus Cohort(2018) QUINTANA, Rosana; PONS-ESTEL, Guillermo J.; ROBERTS, Karen; SACNUN, Monica; SERRANO, Rosa Maria; NIETO, Romina; CONTI, Silvana; GERVASONIL, Viviana; CATOGGIO, Luis J.; SORIANO, Enrique R.; SCOLNIK, Marina; GARCIA, Mercedes; ALVARELLOS, Alejandro; SAURIT, Veronica; BERBOTTO, Guillermo; SATO, Emilia; COSTALLAT, Lilian; BORBA, Eduardo; BONFAL, Eloisa; XAVIER, Ricardo M.; SILVA, Ana Carolina de Oliveira e; MOLINA, J. F.; IGLESIAS-GAMARRA, Antonio; GUIBERT-TOLEDANO, Marlene; REYES, Gil A.; MASSARDO, Loreto; NEIRA, Oscar J.; CARDIEL, Mario H.; BARILE, Leonor; AMIGO, Mary Carmen; SILVEIRA, Luis H.; TORRE, Ignacio Garcia de la; ACEVEDO-VASQUEZ, Eduardo; UGARTE-GIL, Manuel; ALFARO-LOZANO, Jose; SEGAMI, Ines; CHACON-DIAZ, Rosa; SPINETTI, Maria H. Esteva; GOMEZ-PUERTA, Jose A.; ALARCON, Graciela S.; PONS-ESTEL, Bernardo A.- Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors-data from a multi-ethnic Latin American cohort(2014) GARCIA, Mercedes A.; ALARCON, Graciela S.; BOGGIO, Gabriela; HACHUEL, Leticia; MARCOS, Ana Ines; MARCOS, Juan Carlos; GENTILETTI, Silvana; CAEIRO, Francisco; SATO, Emilia I.; BORBA, Eduardo F.; BRENOL, Joao C. Tavares; MASSARDO, Loreto; MOLINA-RESTREPO, Jose Fernando; VASQUEZ, Gloria; GUIBERT-TOLEDANO, Marlene; BARILE-FABRIS, Leonor; AMIGO, Mary-Carmen; HUERTA-YANEZ, Guillermo F.; CUCHO-VENEGAS, Jorge M.; CHACON-DIAZ, Rosa; PONS-ESTEL, Bernardo A.Objectives. The aim of this study was to assess the cumulative incidence, risk and protective factors and impact on mortality of primary cardiac disease in SLE patients (disease duration <= 2 years) from a multi-ethnic, international, longitudinal inception cohort (34 centres, 9 Latin American countries). Methods. Risk and protective factors of primary cardiac disease (pericarditis, myocarditis, endocarditis, arrhythmias and/or valvular abnormalities) were evaluated. Results. Of 1437 patients, 202 (14.1%) developed one or more manifestations: 164 pericarditis, 35 valvulopathy, 23 arrhythmias, 7 myocarditis and 1 endocarditis at follow-up; 77 of these patients also had an episode of primary cardiac disease at or before recruitment. In the multivariable parsimonious model, African/Latin American ethnicity [odds ratio (OR) 1.80, 95% CI 1.13, 2.86], primary cardiac disease at or before recruitment (OR 6.56, 95% CI 4.56, 9.43) and first SLICC/ACR Damage Index for SLE assessment (OR 1.31, 95% CI 1.14, 1.50) were risk factors for the subsequent occurrence of primary cardiac disease. CNS involvement (OR 0.44, 95% CI 0.25, 0.75) and antimalarial treatment (OR 0.62, 95% CI 0.44, 0.89) at or before recruitment were negatively associated with the occurrence of primary cardiac disease risk. Primary cardiac disease was not independently associated with mortality. Conclusion. Primary cardiac disease occurred in 14.1% of SLE patients of the Grupo Latino Americano de Estudio de Lupus cohort and pericarditis was its most frequent manifestation. African origin and lupus damage were found to be risk factors, while CNS involvement at or before recruitment and antimalarial treatment were protective. Primary cardiac disease had no impact on mortality.
conferenceObject Patients Characteristics and Patters of Treatment in Refractory Systemic Lupus Erythematosus Patients in the Pre-Biologic Period: Data from a Multiethnic, Multinational Latin American Lupus Cohort(2018) PONS-ESTEL, Guillermo J.; SCOLNIK, Marina; SORIANO, Enrique R.; HARVEY, Guillermina; QUINTANA, Rosana; GARCIA, Mercedes; SAURIT, Veronica; DRENKARD, Cristina; BERBOTTO, Guillermo; SATO, Emilia; COSTALLAT, Lilian; BONFA, Eloisa; BORBA, Eduardo Ferreira; BRENOL, Joao C. Tavares; SILVA, Nilzio A. da; CAVALCANTI, Andre; IGLESIAS-GAMARRA, Antonio; GUIBERT-TOLEDANO, Marlene; REYES, Gil A.; MASSARDO, Loreto; NEIRA, Oscar; CARDIEL, Mario H.; BARILE, Leonor; AMIGO, Mary Carmen; SILVEIRA, Luis H.; TORRE, Ignacio Garcia de la; SERRANO, Rosa Maria; ACEVEDO-VASQUEZ, Eduardo; UGARTE-GIL, Manuel; SEGAMI, Lees; GERVASONI, Viviana; CONTI, Silvana; CHACON-DIAZ, Rosa; ESTEVA-SPINETTI, Maria H.; PONS-ESTEL, Bernardo A.